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Abstract 
 
Background: Concomitant chemo-radiotherapy (CCRT) has become an indispensable organ, but not 
always function preserving treatment modality for advanced head and neck cancer. To prevent/limit 
the functional side effects of CCRT, special exercise programs are increasingly explored. This study 
presents cost-effectiveness analyses of a preventive (swallowing) exercise program (PREP) compared 
to usual care (UC) from a health care perspective. 
Methods: A Markov decision model of PREP versus UC was developed for CCRT in advanced head 
and neck cancer. Main outcome variables were tube dependency at one-year and number of post-
CCRT hospital admission days. Primary outcome was costs per quality adjusted life years 
(cost/QALY), with an incremental cost-effectiveness ratio (ICER) as outcome parameter. The 
Expected Value of Perfect Information (EVPI) was calculated to obtain the value of further research.  
Results: PREP resulted in less tube dependency (3% and 25%, respectively), and in fewer hospital 
admission days than UC (3.2 and 4.5 days respectively). Total costs for UC amounted to €41,986 and 
for PREP to €42,271. Quality adjusted life years for UC amounted to 0.68 and for PREP to 0.77.  
Based on costs per QALY, PREP has a higher probability of being cost-effective as long as the 
willingness to pay threshold for 1 additional QALY is at least €3,200/QALY. At the prevailing threshold 
of €20,000/QALY the probability for PREP being cost-effective compared to UC was 83%. The EVPI 
demonstrated potential value in undertaking additional research to reduce the existing decision 
uncertainty. 
Conclusions: Based on current evidence, PREP for CCRT in advanced head and neck cancer has 
the higher probability of being cost-effective when compared to UC. Moreover, the majority of 
sensitivity analyses produced ICERs that are well below the prevailing willingness to pay threshold for 
an additional QALY (range from dominance till €45,906/QALY). 
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Background 
 
In recent years, concomitant chemo-radiotherapy (CCRT) has become an indispensable organ 
preserving treatment modality for advanced head and neck cancer, improving local control and overall 
survival in several anatomical sites [1]. Unfortunately, CCRT can have a detrimental effect on many 
functions of the upper respiratory and digestive system. Sequellae such as pain, oedema, xerostomia 
and fibrosis negatively affect mouth opening (trismus), chewing, swallowing and speech [1].
 
Several 
studies investigating long-term effects of CCRT have concluded that swallowing and nutritional 
dysfunction tend to be persistent and can be severe [2-4].
 
Not surprisingly, therefore, CCRT can have 
a negative effect on patients‟ quality of life (QoL) [2]. Moreover, even before onset of treatment 
patients may already present with pain, impaired swallowing, trismus, aspiration, dietary restrictions 
and tube dependency, and loss of body weight, because the tumour may disrupt the normal anatomy 
and thus interfere with normal function [1]. Many studies refer to the importance of rehabilitation after, 
and even during treatment, in order to support and improve those functions [2]. However, as yet, few 
studies have investigated the effects of (preventive) rehabilitation exercises on the predictable and 
inevitable swallowing and mouth opening problems for this patient group. In addition, little is known 
about the costs and benefits of such exercise programs for head and neck cancer. As the clinical 
effectiveness is established [4], it is now relevant to embark on cost-effectiveness as a contribution to 
decision making on coverage.  
The aim of this study was to analyze the incremental cost-effectiveness for a preventive exercise 
program (PREP) versus usual care (UC) for patients with advanced head and neck cancer treated at 
the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL).   
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Methods 
 
Case description 
To investigate the cost-effectiveness of a preventive (swallowing) exercise program (PREP) compared 
to usual care (UC) in advanced head and neck cancer, data of two recent clinical trials in the 
Netherlands Cancer Institute were used [3,4]. In both studies the protocol was approved by the 
Protocol Review Board of the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-
AVL) and written informed consent was obtained from all patients before entering the study. All 
patients had advanced (stage III and IV) functional or anatomical inoperable head and neck cancer [5].
 
All received identical concomitant chemo-radiotherapy (CCRT), which consisted of 100-mg/m
2
 
Cisplatin as a 40 minutes intravenous (IV) infusion on days 1, 22, 43 and combined with radiotherapy, 
and identical intensive supportive care. Details about patients, methods, and clinical results in both 
studies have been published previously [3,4,6]. The patient characteristics are summarized in Table 1.  
The UC data are derived from a multi-center randomized controlled trial (RCT), comparing intra-
arterial (IA) and intravenous (IV) chemo radiation in advanced head and neck cancer [3].
 
Only the data 
of the 53 patients treated at the NKI-AVL, randomized in the IV arm, and still alive and disease free at 
12 months were analysed for this cost-effectiveness study.  
The PREP data are derived from a clinical trial conducted immediately following the former RCT. In 
this second RCT the effects of preventive strength and stretch exercises on (long-term) swallowing 
and/or mouth opening problems caused by CCRT, as an adjunct to UC, were assessed in 55 
advanced head and neck cancer patients [4]. Before treatment all patients were randomized into two 
groups: an experimental group that was provided with the TheraBite® Jaw Motion Rehabilitation 
System™ and a group receiving standard intervention (Standard group). The rationale and a detailed 
description of the exercises have been published previously [4]. In short, both regimes consist of 
comparable stretch and strength exercises to keep the swallowing musculature active before, during, 
and after CCRT, even when patients are not swallowing because of (naso) gastric tube feeding. 
Patients were encouraged to practice 3 times a day and to integrate the exercises into other daily 
activities at home. Participants were provided with verbal and written instructions prior to treatment, at 
which time they also started practicing, thus, when oral intake was not yet influenced by the treatment. 
Thirty-seven of the 55 included patients were still alive and disease free at 12-months. Since no 
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significant differences in QoL, costs and functional outcomes were found between the two arms, for 
the present cost-effectiveness study both PREP arms were taken together [4].  
The main outcome variables of interest for this cost effectiveness assessment were tube dependency 
at 12 months, and number of days patients were admitted to the hospital after completion of the CCRT 
in the first year. In the UC cohort, tube dependency was 13/53 (25%), and in the PREP cohort 1/37 
(3%). The mean number of extra admission days in the hospital post-CCRT was 4.5 (SE 2.8) in the 
UC, and 3.2 (SE 1.2) in the PREP cohort.  
 
Model description 
A Markov decision model was developed to compare the PREP versus UC for advanced head and 
neck cancer. The model was constructed with three mutually exclusive health states: “complete 
remission”, “recurrent disease” and “death” (death of cancer or other causes). The input regarding 
treatment success rates, and probability of recurrence were based on the published outcome data 
from our institute [6]. We assumed that the PREP has no direct influence on survival [7-9]. Input on 
aspiration for UC was based on the empirical data, for PREP the value was assumed, based on the 
literature. The input of feeding substitutes and hospitalization were based on the above-described 
databases: the series of Ackerstaff et al. [3], as UC and that of Van der Molen et al. [4], as the PREP 
strategy. The model simulated the course of events in a hypothetical cohort of 1000 patients aged 55 
years with a stage III or IV squamous cell carcinoma of the head and neck treated at the NKI-AVL. 
Possible complications from the treatment were modelled up to 1 year from the start of treatment.  The 
cycle length of the model was one month, with a total simulated time horizon of 1 year. The analysis 
was performed from the health care perspective of the NKI-AVL. All costs were reported in year 2008 
Euros (Table 2).  
 
Costs 
In the NKI-AVL the costs for treatment where measured by means of clinical pathways that patients 
followed when receiving CCRT. Besides treatment costs, feeding substitutes, pneumonia as adverse 
event and hospital days were derived from the NKI-AVL hospital charts and administration. The 
professional costs of PREP were derived from the Dutch Diagnosis Treatment Combination (DBC) 
“DBC-system” list, this tariff includes all possible involved disciplines in the PREP (19-49 hours for 
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€3,252). Use of feeding substitutes (tube feeding) was calculated per disease severity stage from the 
two databases. It was assumed that from the patients needing tube feeding, 50% received a nasal 
tube and 50% received a gastronomy-tube (Table 2). 
 
Health effects 
The quality of life of patients treated with CCRT was examined by Ackerstaff et al. [3]. For UC during 
treatment the QoL result of 7 weeks was incorporated (0.517), for UC after treatment, the QoL result of 
12 months was taken (0.754) [3]. Assumptions as to how these results would be influenced by the 
PREP were based on published literature and informal expert elicitation (Table 2). 
 
Analysis 
We programmed the model in Microsoft Excel (Microsoft, Redmond, WA) and validated it using 
various sensitivity analyses. Future costs and effects were discounted to their present value by a rate 
of 4% and 1.5% per year respectively, according to Dutch guidelines [10]. Incremental cost-
effectiveness ratios (ICERS) were calculated by dividing the incremental costs by incremental quality 
adjusted life years (QALYs). Stochastic uncertainty in the input parameters was handled 
probabilistically, by assigning distributions to parameters (Table 2) [11]. Parameter values were drawn 
randomly from the assigned distributions, using Monte Carlo simulation with 1000 iterations. The 
results of the simulation of the hypothetical cohort of 1000 patients are illustrated in a Cost-
Effectiveness (CE) plane, each quadrant indicates whether a strategy is more or less expensive and 
more or less effective [12]. Cost-effectiveness acceptability curves (CEACs) to show decision 
uncertainty are presented. CEACs show the probability that a pathway has the highest net monetary 
benefit, and thus is deemed cost-effective, for a range of Willingness to Pay (λ) values for one 
additional QALY, also referred as the ceiling ratio. This definition involves a Bayesian definition of 
probability i.e. the probability that the hypothesis („PREP is cost-effective compared to UC') is true 
given the data. The two curves therefore always sum to 100% for one given value of λ [13]. In the 
Netherlands an informal ceiling ratio of €80,000 per QALY exists (Dutch Council for Public Health and 
Health Care 2006), and for preventive care programs of €20,000 per QALY. The National Institute for 
Health and Clinical Excellence in the United Kingdom uses a general ceiling ratio between £20,000-
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£30,000 per QALY. In this analysis, we use the Dutch threshold for preventive care programs, 
€20,000 per QALY. 
 
Sensitivity Analyses 
We performed four one-way sensitivity analyses. The first two sensitivity analyses tested the 
robustness of the model outcomes against changes in the utility estimates (i.e. higher and lower 
estimates), as the current estimates are preliminary. For the two other sensitivity analyses, lower and 
higher cost estimates (€1,213 and €7,058) were imported for the resource use associated with 
paramedical care delivery in the rehabilitation program (for respectively 7-18 hours or 50-129 hours).  
In addition, we performed two two-way sensitivity analyses to test the most uncertain parameters, 
such as a variation in utilities in combination with the various DBC tariffs, and the variation of utilities in 
combination with the probability of aspiration.  
For various scenarios regarding costs and QALYs, we also present the findings as cost-effectiveness 
acceptability frontiers that illustrate the probability of any intervention being optimal compared to its 
alternative. The optimal intervention is defined as the one with the highest expected net health benefit. 
Each cost-effectiveness frontier also illustrates the potential crossover when one intervention is 
substituted by another as the one with the highest probability of being optimal, and therefore provides 
useful information for policy makers.  
 
Expected value of perfect information (EVPI) 
Uncertainty in the cost-effectiveness results was also presented and used to inform future research 
priorities using Value of information analysis (VOI) analyses based on the expected value of perfect 
information (EVPI). VOI can be used to support decisions on focus and design of further research, 
assuming that additional evidence on the relevant aspects can be desired, but that the amount and 
specific requirements for further research will depend on the parameters which are causing the most 
uncertainty [14].
 
Generally, information is valuable when there is great uncertainty surrounding a 
decision and when that decision likely affects a large number of people in a meaningful way. If one 
had perfect information about the risks and benefits of a particular technology, decision makers in 
theory would always be able to make correct choices regarding the use of the technology. The 
difference between the expected net benefit obtained using perfect information and the expected net 
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benefit obtained in the presence of uncertainty (that is, the maximum expected net benefit obtained 
with less than perfect information) is known as the expected value of perfect information (EVPI). It can 
be interpreted as the maximum amount the decision maker would be willing to spend to obtain perfect 
information [15]. 
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Results 
 
Mean results 
The total health care costs (treatment costs + preventive exercises) per patient were: €42,271 for the 
preventive exercise program (PREP), and €41,986 for usual care (UC). The quality adjusted life years 
amounted to: 0.77 (PREP), and 0.68 (UC). The difference in costs per QALY of the PREP strategy 
compared to the UC strategy amounted to €285 (=0.7% of the total treatment costs). In comparison to 
UC, the PREP for advanced head and neck tumours costs €3,197 per QALY gained and was found to 
be more effective and slightly more costly (Table 3). 
 
Uncertainty Analyses  
When focusing on quality adjusted survival, the PREP has a higher probability of being cost-effective 
compared to UC, as long as the willingness to pay threshold for 1 additional QALY is at least 
€3,200/QALY (Figure 1 and 2). At the prevailing threshold of €20,000/QALY the probability for PREP 
being cost-effective compared to UC was 83%.  
 
Sensitivity analyses 
The sensitivity analysis using lower utility estimates resulted in an incremental cost-effectiveness ratio 
(ICER) of €6,393/QALY; higher utilities resulted in an ICER of €2,131/QALY. The sensitivity analysis 
considering a lower resource use (fewer hours of professionals) resulted in UC being dominated by 
PREP, i.e. PREP is more effective and less costly than UC. Modelling a higher resource use (more 
hours) for the PREP resulted in a higher ICER of €45,906/QALY (Figure 3). The results of the two-way 
sensitivity analyses are listed in Table 4, the majority of the analyses resulted with an ICER below the 
ceiling ratio of €20,000/QALY. 
 
Expected value of information (EVPI) 
At a ceiling ratio of €20,000/QALY the probability for PREP being cost-effective compared to UC was 
83%, which shows a considerable decision uncertainty using the current available data. The EVPI for 
the base case resulted in €398,063, providing the upper boundary for investing research funds in 
further clinical trials to obtain perfect information on the cost-effectiveness of PREP versus UC.  The 
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EVPI demonstrated potential value in undertaking additional research to reduce the existing decision 
uncertainty (Figure 4). 
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Discussion 
 
This cost-effectives analysis, as based on two patient populations with advanced head and neck 
cancer treated with CCRT of which one was additionally treated with a preventive exercise program 
(PREP) to prevent or limit the functional side effects of the treatment, and one receiving no additional 
care, showed that quality-adjusted survival was higher for the PREP. When focusing on quality 
adjusted survival, PREP has an 83% probability of being cost-effective at the prevailing threshold of 
€20,000/QALY.  
Because the presented results are based on preliminary data, assumptions had to be made regarding 
the utilities and no empirical data was yet available regarding decrease of e.g. aspiration, which can 
be a life threatening problem in case of severe swallowing problems resulting from CCRT. However, a 
quarter of the patients in the usual care cohort needed a feeding tube at 12 months, in contrast to only 
3% in the PREP cohort. This suggests that patients in the UC group are more likely to suffer from 
aspiration than those in the PREP, something worthwhile to look into in more detail in future studies. 
Furthermore, not all relevant improvements can easily be expressed in costs or utilities and this may 
be even more difficult because of the various different effects that rehabilitation may have. E.g., it is 
likely that the assumptions regarding the incremental utility of the PREP and the probability of 
aspiration are an underestimation, because patients‟ functional improvement is likely to become even 
better when patients are receiving the full rehabilitation program. This is partly covered by the 
sensitivity analyses but may also be investigated in more detail with a Contingent Valuation study, 
where someone‟s willingness to pay for improvements in specific aspects of quality of life can be 
assessed.  
Another limitation of this cost-effective analysis is that the patient distribution in the two cohorts is not 
completely comparable. Although all patients had stage III or IV disease, the distribution according to 
stage (more stage IV in the UC group) and anatomical site (no oral cavity/oropharynx in the UC group) 
was somewhat different. Next to this, the chemotherapy type and scheme in both cohorts was identical 
except with respect to the application of radiotherapy. In the IV arm of the study of Ackerstaff et al. [3], 
roughly one fourth of the patient population was treated with intensity-modulated radiotherapy (IMRT), 
whereas in all patients in the study of Van der Molen et al. [4] IMRT was applied. These differences 
could have influenced the functional outcomes in the two cohorts. Exact data about these aspects 
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unfortunately are not retrievable. But we are sufficiently confident, that in the study of Ackerstaff et al. 
[3] most of the patients that were disease free at 1-year, indeed received IMRT. 
Literature suggests that other functions will also improve as a result of a PREP, and thus the cost-
effectiveness would most likely improve even more when these other functions are taken into account 
[16-22].
 
Model inputs for UC were based on a former study performed in the Netherlands Cancer 
Institute (NKI-AVL) [3], to be able to make a clear comparison. However, the NKI-AVL, as a 
specialized tertiary care hospital, is a pioneer in this field and thereby already had implemented some 
rehabilitation components in the UC-series of Ackerstaff et al. [3], e.g. not „automatically‟ providing a 
feeding tube at the onset of treatment, but trying with intensified support to maintain oral feeding for as 
long as possible. If the comparison was made with the care as provided by the national guidelines at 
that time, the analysis would probably result in an even more favourable ICER. 
Because of the promising results of this PREP, a more comprehensive head and neck rehabilitation 
program has been developed to stimulate participation in everyday life activities with all the 
pathophysiological or anatomical changes and restrictions accompanying head and neck cancer taken 
into account. To achieve this, the NKI-AVL is cooperating with the rehabilitation centre Amsterdam 
(READE) to accomplish this comprehensive rehabilitation program based on the 'International 
Classification of Functioning, Disability and Health' (ICF) core sets for head and neck cancer [23]. It is 
conceivable that such a more intensified program can boost rehabilitation results even further and 
research as to that is planned. 
This cost-effectiveness analysis is based on a Markov decision model because this allows 
synthesizing data from various sources, when an empirical, longer term, head to head trial of PREP 
versus UC has not yet been performed. As with all modelling studies that extrapolate data beyond the 
time horizon of a clinical trial, the outcomes have to be interpreted as expected costs and outcomes, 
based on the best available current evidence. 
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Conclusion 
This study shows that, based on current available evidence, the addition of a preventive (swallowing) 
exercise program to concomitant chemo-radiotherapy in advanced head and neck cancer improves 
quality-adjusted survival and has a higher probability of being cost-effective compared to usual care. 
The calculated additional costs of €3,200/QALY is well below the threshold of €20,000/QALY, which 
currently is handled for preventive care programs e.g. by the Dutch Council for Public Health and 
Health Care and the National Institute for Health and Clinical Excellence in the United Kingdom. With a 
relatively low additional investment in research the uncertainty in the calculation of the cost 
effectiveness can be considerably improved, which is currently ongoing.  
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Table 1. Patient characteristics of the preceding randomized CCRT trial at in the NKI-AVL of 
Ackerstaff et al. (usual care) [3] and the randomized CCRT trial at the NKI-AVL of Van der Molen et 
al.[4]
  
that included a preventive swallowing exercise program (PREP). 
  
Usual care 
N=53 
 
 
PREP 
N=37 
Age in years 
Median 
Range 
 
 
55 
24-75 
 
58 
39-77 
Sex 
Male 
Female 
 
 
36 (68%) 
17 (32%) 
 
28 (76%) 
9 (24%) 
Stage distribution 
III 
IV 
 
 
14 (26%) 
39 (74%) 
 
14 (38%) 
23 (62%) 
Tumour site 
Oral cavity/oropharynx 
Hypopharynx 
Nasopharynx 
 
42 (79%) 
11 (21%) 
 
16 (43%) 
15 (41%) 
6 (16%) 
 
Follow up  
Pre 
7 wks 
1-year 
 
 
Pre 
10 wks 
1-year 
Tube dependency 
before CCRT 
1-year after CCRT
 
 
 
8 (15%) 
13/53 (25%) 
 
0 (0%) 
1/37 (3%) 
Aspiration at 1-year  
Unknown 
 
 
1/37 (3%) 
 
Hospital admission days after completion of 
CCRT (mean per patient/year) 
 
 
4.49 
 
3.19 
Single day admissions after completion of CCRT 
(mean per patient/year) 
 
 
0.70 
 
0.16 
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Table 2. Input Parameters of base case and sensitivity analysis, including days of feeding substitutes, 
treatment success rates, aspiration probabilities, utilities and costs. 
Parameter Mean SE Distribution Source 
Care 
Days FS RB 2 months 0.760
a
   4 
Days FS UC 2 months 0.820   3 
Days FS RB 3 months 0.370   4 
Days FS UC 3 months 0.700   3 
Days FS RB 12 months 0.030   4 
Days FS UC 12 months 0.240   3 
Success rates 
CCRT 0.940
b
 0.030 Beta 5 
Recurrence rates 0.012
c
 0.010 Beta 5 
Aspiration PREP 0,027 0.015 Beta 4 
Aspiration UC 0,054 0.015 Beta Assumption 
Utilities 
During CCRT PREP 0.617 0.015 Beta Assumption 
During CCRT UC 0.517 0.015 Beta 3 
Cured PREP 0.854  0.015 Beta Assumption 
Cured UC 0.754 0.015 Beta 3 
Recurrent disease 0.517 0.015 Beta Assumption 
Costs 
Hospital days NKI € 476 Fixed  8 
Day care NKI € 229 Fixed  8 
Feeding substitutes € 845 Fixed  NKI-AVL 
Professional Tariff  € 3,252 Fixed  DBC-system 
CCRT € 31,000 Fixed  NKI-AVL 
Palliative care € 30,000 Fixed  Assumption 
Pneumonia € 1,904 Fixed  3, 4, 7 
Sensitivity analysis     
Utilities      
During CCRT PREP low 0.567 0.015 Beta Assumption 
During CCRT PREP high 0.667 0.015 Beta Assumption 
Cured PREP low 0.804  0.015 Beta Assumption 
Cured PREP high 0.904  0.015 Beta Assumption 
Costs     
Professional Tariff low € 1,214 Fixed  DBC-system 
Professional Tariff high € 7,058 Fixed  DBC-system 
PREP= preventive exercise program 
UC= usual care 
FS= feeding substitutes 
NKI= Netherlands Cancer Institute 
CCRT= concomitant chemo-radiotherapy 
FS= Feeding substitutes 
SE= Standard deviation 
a
 calculated to monthly rate 
b
 progression free survival probability of 50% over 5 years calculated to monthly survival rate 
c
 recurrence rate from 'complete remission' to recurrent disease 
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Table 3. Results of the base case analysis; incremental (difference) in QALYs, incremental costs and 
the incremental cost-effectiveness ratio (ICER) of the comparison between Usual Care and PREP 
 
 Costs QALYs Incremental 
COSTS 
Incremental 
QALYS 
ICER 
Costs/QALY 
PREP €42,271 0.77 €285 0.09 €3,197* 
Usual Care €41,986 0.68    
 
*The numbers might not add up to 100% because of rounding; 284.8849/0.0891=3197.3614 
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Table 4. Results of the two-way sensitivity analysis; range of variables of utilities versus different DBC 
tariffs and range of variables of utilities versus different aspiration probabilities 
Utilities 
DBC tariffs 
0.80 0.85 0.90 
€ 1,214 -€  39,349 -€ 19,674 -€ 13,116 
€ 3,252 € 6,394 € 3,197 € 2,131 
€ 7,058 € 91,814 € 45,907 € 30,605 
Utilities 
aspiration 
0.80 0.85 0.90 
0.02 € 23,442 € 11,721 € 7,814 
0.04 € 13,430 € 6,715 € 4,477 
0.06 € 3,417 € 1,709 € 1,139 
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Figure legend: 
 
Figure 1: Cost-Effectiveness plane; scatter plot showing the mean differences in costs and outcomes 
from the data using 1000 bootstrap replicates. 
 
Figure 2: Cost-effectiveness Acceptability Curves (CEAC); presenting the probability that the PREP is 
cost-effective compared with the Usual Care for a range of values of thresholds (ceiling ratios, 
willingness to pay for one QALY). 
 
Figure 3: CEAC-frontiers; plotting the extent of uncertainty associated with the optimal strategy 
 
Figure 4: Expected Value of Perfect Information (EVPI) for the population, base case analysis. 
 
 
Figure 1. Cost-Effectiveness plane; scatter plot showing the mean differences in costs and outcomes 
from the data using 1000 bootstrap replicates. 
-€ 4,000 
-€ 2,000 
€ 0 
€ 2,000 
€ 4,000 
€ 6,000 
€ 8,000 
€ 10,000 
0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00
In
c
re
m
e
n
ta
l c
o
s
ts
Incremental QALYs

Figure 1
Figure 2. Cost-effectiveness Acceptability Curves (CEAC); presenting the probability that the PREP is 
cost-effective compared with the Usual Care for a range of values of thresholds (ceiling ratios, 
willingness to pay for one QALY). 
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Figure 2
Figure 3. CEAC-frontiers; plotting the extent of uncertainty associated with the optimal strategy 
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Figure 3
Figure 4. Expected Value of Perfect Information (EVPI) for the population, base case analysis. 
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